Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.7852W HIGH $57.14
Volume
93.50 K
Value Traded
5.53 M
Short % Float
0.42%
-5.66%Week
-36.02%1 Month
-39.51%3 Month
-26%6 Month
+153.93%5 Year
+125.95%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.20 B
EPS (TTM)
-0.57
P/E Ratio
-
Ent. Value
2.10 B
Total Shares
50.62 M
Float Shares
41.61 M
Insiders
18.09%
Institutions
0.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
NBTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Nanobiotix S.A.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nanobiotix S.A.
610Total events
6Upcoming
114Tier-1 (high impact)
2014 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Arnd Christ appointed Chief Financial Officer and executive board member
▲Full ResultsNBTXR3ApprovedClinical Data
Complete full cohort Phase 1 results for JNJ-1900 (NBTXR3) in recurrent NSCLC presented at IASLC 2026 WCLC
Inoperable, locoregionally recurrent non-small cell lung cancer (NSCLC)source ↗
●Poster PresentationNBTXR3ApprovedPresentation
Poster presentation of Phase 1 reRT with NBTXR3 data at IASLC 2026 WCLC
Inoperable, locoregionally recurrent non-small cell lung cancer (NSCLC)source ↗
▲Enrollment CompleteNBTXR3ApprovedTrial
Enrollment complete in dose-escalation and expansion parts of Phase 1 NSCLC study
Inoperable, locoregionally recurrent non-small cell lung cancer (NSCLC)source ↗
▲Full ResultsNBTXR3ApprovedClinical Data
Full cohort analysis results from Phase 1 NSCLC study reported
inoperable, locoregionally recurrent non-small cell lung cancer (NSCLC)source ↗
▲Dose Finding UpdateNBTXR3ApprovedTrial
Recommended Phase 2 dose established at 33% of gross tumor volume
inoperable, locoregionally recurrent non-small cell lung cancer (NSCLC)source ↗
▲Protocol AmendmentNBTXR3ApprovedTrial
FDA clearance for protocol amendment to Phase 3 NANORAY-312
Cisplatin-ineligible Head and Neck Cancersource ↗
▲Oral PresentationNBTXR3ApprovedPresentation
Phase 1 NSCLC data presented at 2026 WCLC Meeting
inoperable, locoregionally recurrent non-small cell lung cancer (NSCLC)source ↗
▼Equity OfferingCorporate
Closing of global offering including full exercise of underwriters' option, raising approximately $100 million
▼Equity OfferingCorporate
Full exercise of overallotment option for global offering, raising $100M gross proceeds
▼Equity OfferingCorporate
Suspension of trading for global offering of ADS and ordinary shares
▲Oral PresentationNBTXR3ApprovedPresentation
Presentation of Part 1 data from CONVERGE study at ESTRO 2026
stage 3 inoperable non-small cell lung cancersource ↗
▲Protocol AmendmentNBTXR3ApprovedTrial
FDA acceptance of protocol amendment for NANORAY-312 removing interim analysis and modifying final analysis
locally advanced squamous cell carcinoma of the head and necksource ↗
●Poster PresentationPresentation
Poster #6389: Maximizing systemic LNP-DNA delivery for cancer-activated expression of Immunotherapy agents using Nanoprimer technology at AACR 2026
cancersource ↗
●Oral PresentationPresentation
Conference Call and Webcast for Business Update and FY2025 Results
▲FDA Filing AcceptedRegulatory Filing
Filing of Universal Registration Document (URD) with AMF and Form 20-F with SEC
◆Poster PresentationNBTXR3ApprovedPresentation
First data from CONVERGE study presented at 2026 European Lung Cancer Conference
stage 3 inoperable non-small cell lung cancersource ↗
▲Oral PresentationNBTXR3ApprovedPresentation
CONVERGE Part 1 data updated at ESTRO 2026
Stage 3 unresectable NSCLCsource ↗
▲Protocol AmendmentNBTXR3ApprovedTrial
FDA accepted protocol amendment for NANORAY-312 removing interim analysis and modifying final analysis to require fewer events
Head and neck cancer (cisplatin-ineligible)source ↗
▲Poster PresentationnanoprimerPresentation
Preclinical data on nanoprimer pretreatment followed by recombinant DNA-LNP presented at AACR 2026
Anti-tumor immunotherapysource ↗
◆Interim AnalysisNBTXR3ApprovedTrial
Interim analysis for NANORAY-312 expected after required events and last patient recruited in 1H 2026
locally advanced head and neck squamous cell carcinomasource ↗
◆Enrollment CompleteNBTXR3ApprovedTrial
Last patient recruited in NANORAY-312
locally advanced head and neck cancersource ↗
▲Additional DataNBTXR3ApprovedClinical Data
CONVERGE Phase 2 Part 1 data presented at ELCC 2026 and updated at ESTRO 2026
Stage 3 unresectable NSCLCsource ↗
▲Preclinical PoCnanoprimerPreclinical
New preclinical data for Nanoprimer presented at 2026 AACR Meeting
anti-tumor immunotherapysource ↗
▲Topline ReadoutNBTXR3ApprovedClinical Data
Part 1 data from J&J-led Phase 2 CONVERGE study presented
Stage 3 unresectable NSCLCsource ↗
▲Poster PresentationnanoprimerPresentation
Nanoprimer preclinical data presented at 2026 AACR Meeting
anti-tumor immunotherapysource ↗
▲Debt Royalty FinancingCorporate
Closed royalty financing with HCRx, upfront payment of $50 million
▲Trial InitiationNBTXR3ApprovedTrial
Completed sponsorship transfer of NANORAY-312 to Johnson & Johnson in majority of regions
locally advanced head and neck cancer (cisplatin-ineligible)source ↗
◆Oral PresentationPresentation
Nanobiotix participates in Jefferies London Healthcare Conference fireside chat
▲Patent GrantedIP / Competition
Four new patent applications filed for Curadigm Nanoprimer platform
▲Preclinical PoCPreclinical
In vivo preclinical data presented at PODD 2025 for Nanoprimer with therapeutic vaccines
cancersource ↗
●Oral PresentationPresentation
Presentation at PODD 2025: Nanoprimer Technology for Enhanced Therapeutic Delivery
cancersource ↗
●Manufacturing MilestoneCMC / Inspection
CMC activities launched for Curadigm Nanoprimer platform
◆Oral PresentationPresentation
Guggenheim Annual Healthcare Innovation Conference fireside chat
Past FDA Catalysts and PDUFA Decisions
How NBTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | JNJ-1900 (NBTXR3) | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$48M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 76%
Micro Cap(rank 502 of 660)
Percentile Rank
Nanobiotix S.A. faces pipeline headwinds (27/100), with $161M risk-adjusted pipeline value, led by NBTXR3 in Radiotherapy (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NBTXR3 UnknownMarketedNCT01433068 | Adult Soft Tissue Sarcoma | Phase 2 | COMPLETED | 202 | Feb 1, 2015 |
Clinical Trial Results
Readouts, endpoints and source filings for every NBTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| JNJ-1900 (NBTXR3) Fast Track | non-small cell lung cancer | Phase 1 | 2026-09-24 | one year locoregional control rate: 79%; one year local progression free survival: 61%; one year overall survival: 70%Read More | NANOBIOTIX Provides First Half 2026 Operational and Financial UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NBTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % | 376.00 K | 105.05 K | -60.52% ( -161.04 K) |
NBTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NBTX ranks across every disease it competes in
Competitive Position is a premium feature
See how NBTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNBTX News
NBTX▼ -7.7%on this news
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
Nanobiotix has appointed Arnd Christ as its new Chief Financial Officer, effective October 1, 2026. With over 25 years of experience in financial leadership within biotechnology, Mr. Christ succeeds Bart Van Rhijn, who has served for five years. His expertise is expected to support Nanobiotix's growth as it expands its treatment platforms.
Read more →NBTXNANOBIOTIX Provides First Half 2026 Operational and Financial Update
NANOBIOTIX reported encouraging operational and financial updates for the first half of 2026, highlighting positive results from the Phase 1 study of JNJ-1900 in non-small cell lung cancer. The company successfully raised €86 million through a follow-on offering, extending its cash runway into 2029. Additionally, the FDA approved a protocol amendment for the Phase 3 NANORAY-312 study in head and neck cancer, further supporting its clinical development efforts.
Read more →NBTXVoting Rights and Shares Capital of the Company
Nanobiotix, a late-stage clinical biotechnology company, is focused on developing physics-based therapeutic approaches to enhance treatment outcomes. The company is headquartered in Paris and has been publicly listed since 2012. With a robust patent portfolio, Nanobiotix aims to address various medical conditions, including oncology and central nervous system disorders.
Read more →NBTXNANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
NANOBIOTIX announced positive results from the Phase 1 study of JNJ-1900 (NBTXR3) for inoperable, recurrent non-small cell lung cancer. All 24 patients completed treatment without significant toxicities, achieving a one-year overall survival rate of 70%. The study suggests that JNJ-1900 may allow for effective local control with lower radiation doses. Further patient enrollment is planned following these encouraging findings.
Read more →NBTXNANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Nanobiotix will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. CEO Laurent Lévy and CFO Bart Van Rhijn will present during a fireside chat. The company focuses on physics-based therapeutic approaches to enhance cancer treatment outcomes and has a strong patent portfolio in nanotechnology.
Read more →NBTXNANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment
Nanobiotix announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 15, 2026. The discussion will feature key executives, including co-founder Laurent Lévy and CFO Bart Van Rhijn. This engagement highlights Nanobiotix's commitment to advancing its innovative cancer treatment approaches.
Read more →NBTXNanobiotix Provides First Quarter 2026 Operational and Financial Update
Nanobiotix reported a strong operational and financial update for Q1 2026, highlighting a successful €86.1 million follow-on offering. The company presented promising data from the Phase 2 CONVERGE study of JNJ-1900 (NBTXR3) for NSCLC, showing an 85.7% overall response rate. Additionally, the FDA accepted a protocol amendment for the NANORAY-312 study, enhancing the study's design.
Read more →NBTXNanobiotix rejoint l'indice Euronext Tech Leaders
Nanobiotix has announced its inclusion in the Euronext Tech Leaders index, which aims to enhance the visibility of high-growth European tech companies. This recognition reflects the company's advancements in nanotechnology and its commitment to developing innovative therapeutic approaches for cancer and other diseases. The initiative will provide Nanobiotix with increased exposure to international investors and support for long-term growth.
Read more →NBTXNanobiotix Joins the Euronext Tech Leaders Index
Nanobiotix has been included in the Euronext Tech Leaders Index, highlighting its innovative contributions in nanotechnology and medicine. This recognition reflects the company's growth and potential in addressing significant medical needs. CEO Laurent Levy emphasized the importance of physics-based innovation in healthcare. The initiative aims to enhance visibility for leading technology companies in Europe.
Read more →NBTXNANOBIOTIX Announces Closing of Global Offering
Nanobiotix has successfully closed its global offering, raising approximately $100 million. The offering included the full exercise of the underwriters' option to purchase additional shares. The proceeds will primarily support the advancement of its Nanoprimer platform and other corporate purposes. The company expects these funds will sustain its operations into 2029.
Read more →NBTXNANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
Nanobiotix has announced the full exercise of the underwriters' over-allotment option in its global offering, resulting in gross proceeds of about $100 million. The offering includes 33,805 additional American Depositary Shares (ADSs) priced at $38.98 each. The company plans to allocate the funds primarily towards advancing its Nanoprimer platform and other corporate purposes.
Read more →NBTX▼ -6.9%on this newsshared move
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
Nanobiotix has announced the pricing of its oversubscribed €85 million global offering, which includes a public offering of American Depositary Shares (ADSs) and Ordinary Shares. The offering is expected to yield approximately $98.6 million in gross proceeds, aimed at advancing its cancer treatment platforms. The expected closing date for the offering is May 26, 2026.
Read more →NBTX▼ -6.9%on this newsshared move
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
Nanobiotix has announced the resumption of trading for its ordinary shares on Euronext Paris. This follows a temporary halt to facilitate a public offering of American Depositary Shares and other securities. The company is focused on innovative, physics-based approaches to cancer treatment and holds numerous patents in the biotechnology field.
Read more →NBTX▼ -6.9%on this newsshared move
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
Nanobiotix has announced a temporary halt in trading of its ordinary shares on Euronext Paris at the company's request. This decision is part of a global offering that includes both U.S. and international offerings. Trading is expected to resume later the same day, allowing for the confirmation of allocations and pricing announcements.
Read more →NBTX▼ -6.6%on this newsshared move
Nanobiotix Announces Launch of Global Follow-On Offering
Nanobiotix has announced a global follow-on offering of approximately €75 million to support its cancer treatment developments. The offering includes American Depositary Shares and Ordinary Shares, targeting qualified investors in Europe and the U.S. The company plans to use the proceeds for its Nanoprimer platform and other corporate purposes. The final terms will be determined after a book-building process.
Read more →NBTXNanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Nanobiotix announced positive results from Part 1 of the CONVERGE study, a Phase 2 clinical trial evaluating JNJ-1900 (NBTXR3) in patients with stage 3 inoperable non-small cell lung cancer. The data presented at ESTRO 2026 indicated an overall response rate of 85.7% and a complete response rate of 57.1%. The treatment was found to be feasible and safe, with a 100% disease control rate observed in the study.
Read more →NBTX▼ -11.3%on this news· ran to +21% by day 3
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
Nanobiotix announced FDA acceptance of a protocol amendment for its NANORAY-312 study, which modifies the final analysis to include fewer events and be conducted sooner. This change could expedite the global registration pathway for JNJ-1900 (NBTXR3) in head and neck cancer, potentially leading to earlier revenue generation. The company expects the modified analysis to read out in the same timeframe as the previous interim analysis.
Read more →About Nanobiotix S.A.
BIOPHARMAWATCH ELITE PLUS
Trade the next NBTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime